Bal Pharma Ltd. Hits Upper Circuit on BSE, 9 September 2026

On 9 September 2026 at 10:50 am, Bal Pharma Ltd. (BALPHARMA) hit the upper circuit on BSE at Rs 114.02, a 20% positive move from the previous close of Rs 95.02. The company's market cap stood at Rs 147.81 crore. The upper circuit price for the session was Rs 114.45.

The move was driven by buying interest against the exchange-defined price band. The stock finished the session at its upper circuit level, which makes the day worth noting for short-term market participants.

Key Takeaways

• Bal Pharma Ltd. (BALPHARMA) hit the upper circuit on BSE at Rs 114.45 on 9 September 2026.
• The session move was +20% against a previous close of Rs 95.02.
• Market capitalisation stood at Rs 147.81 crore with a PE ratio of 20.99.
• No official company announcement or verified catalyst was confirmed at the time of writing.
• A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric	Value
Stock	Bal Pharma Ltd.
Current Price / LTP	Rs 114.02
Day Move	20%
Previous Close	Rs 95.02
Day Open	Rs 94.94
Day High	Rs 114.02
Day Low	Rs 94.94
Upper Circuit Price	Rs 114.45
Upper Circuit Limit	Rs 114.02
Market Cap	Rs 147.81 crore
Selected Exchange	BSE
PE Ratio	20.99

All figures above are as of 9 September 2026 at 10:50 am IST, sourced from Univest market data for the BSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

Bal Pharma Ltd. opened at Rs 94.94 on BSE, compared with a previous close of Rs 95.02. During the session, the stock traded between Rs 94.94 and Rs 114.02 before touching the upper circuit price of Rs 114.45.

The absolute day change was Rs 19, while the percentage move was 20%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range, turnover, and previous-close values can differ across exchanges. This article uses BSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 114.02, which is the level the price reached.

Why Bal Pharma Ltd. Hit Upper Circuit

Bal Pharma Ltd. hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action, turnover, and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

The stock held firm through the session and eventually reached the upper circuit level of Rs 114.45.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For Bal Pharma Ltd., the captured upper circuit price was Rs 114.45 on 9 September 2026 at 10:50 am.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

Bal Pharma Ltd. Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For Bal Pharma Ltd., PE ratio was 20.99, PB ratio was 1.81, book value was Rs 52.36, EPS was 4.53, ROE was 10.34%, ROCE was 12.33% and dividend yield was 1.26%, on a market cap of Rs 147.81 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

A PB ratio above 1 means the market price was above the reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

Bal Pharma Ltd. belongs to the Pharmaceuticals & Drugs industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company	Market Cap	PE	PB	ROE
Ind-Swift Laboratories Ltd.	Rs 3185.4 crore	58.92	2.26	-0.78%
Hikal Ltd.	Rs 2996.82 crore	-	2.55	15.22%
Dishman Carbogen Amcis Ltd.	Rs 2687.26 crore	168.67	0.41	-2.89%
Sakar Healthcare Ltd.	Rs 2467.96 crore	71.37	7.7	11.88%
Windlas Biotech Ltd.	Rs 2382.97 crore	35.66	4.61	12.87%

A dash in the PE column means no PE ratio was carried for that company in the source data, which happens when reported earnings are negative or have not been refreshed. Those companies are left out of the average below rather than counted as zero.

Several of these peers are far larger by market capitalisation than Bal Pharma Ltd. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

Bal Pharma Ltd.'s PE ratio was 20.99, compared with an available peer/sector PE average of 66.92, calculated from the 4 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Technical and Ownership Snapshot

The technical snapshot adds context: RSI was 46.5, the 50-day moving average was 86.96 and the 200-day moving average was 79.8.

Shareholding details were not available in the latest market dataset, so no conclusion is drawn about promoter, institutional, or public-shareholder activity.

What Readers Should Know

The main confirmed fact is that Bal Pharma Ltd. hit the upper circuit on BSE at Rs 114.45 on 9 September 2026 at 10:50 am, with a 20% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did Bal Pharma Ltd. hit upper circuit on 9 September 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was BALPHARMA share price on 9 September 2026?

The last traded price used in this article was Rs 114.02 on BSE.

What was the upper circuit price for BALPHARMA?

The upper circuit price was Rs 114.45. The stated exchange upper circuit limit was Rs 114.02. The event numbers in this article are aligned to BSE.

What is Bal Pharma Ltd.'s market cap and PE ratio?

Bal Pharma Ltd.'s market cap was Rs 147.81 crore. PE ratio was 20.99.

Which exchange and data source were used?

The selected exchange was BSE. The article uses Univest market data available at the time of generation, captured on 9 September 2026 at 10:50 am.

Does hitting an upper circuit mean Bal Pharma Ltd. is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell Bal Pharma Ltd. shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether turnover holds up and whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For Bal Pharma Ltd. the stated limit was Rs 114.02. For this session, Bal Pharma Ltd. moved 20%.

Footer Disclosure

Generated on 9 September 2026 at 10:50 am using Univest market data. This article is for informational purposes only and does not constitute investment advice. SEBI RIA registration number INA000017639.